Home › Compare › ENETF vs ABBV
ENETF yields 400000.00% · ABBV yields 3.06%● Live data
📍 ENETF pulled ahead of the other in Year 1
Combined, ENETF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENETF + ABBV for your $10,000?
Ethernity Networks Ltd. provides technology solutions for telecom, mobile, security, and data center markets in Asia, Europe, Israel, and the United States. The company develops and delivers data processing technology and solutions for carrier Ethernet switching, including broadband access, mobile backhaul, carrier Ethernet demarcation, and data centers. It provides ENET flow processors for telco/cloud network; ACE-NIC40 SmartNIC, an open flow enabled software acceleration NIC; ACE-NIC40 SmartNIC, an open flow enabled software acceleration NIC; ACE-NIC50 SmartNIC, which offers 10/25G Ethernet connectivity and field-programmable gate array (FPGA) acceleration; ACE-NIC100 SmartNIC that provides flexible 10/25/40/100G Ethernet connectivity and programmable FPGA acceleration; ENET UEP-60, a programmable routing appliance for 5G, OpenRAN, and Network Edge; and ACE-NIC100 SmartNIC that provides flexible 10/25/40G/100G Ethernet connectivity and programmable FPGA acceleration. The company also offers ENET network appliances, such as ENET UEP-20 universal edge platform and ENET UEP-60 universal edge platform. In addition, it provides FPGA based networking and security solutions to telco/cloud equipment manufacturers and system integrators. The company was formerly known as Neracore Ltd. and changed its name to Ethernity Networks Ltd. in August 2004. Ethernity Networks Ltd. was incorporated in 2003 and is headquartered in Airport City, Israel.
Full ENETF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.